Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure
The product will be manufactured at Lupin’s Nagpur facility in India
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
Yesafili, received marketing authorization approval from the European Commission for the European Union
US business grew by +12.8% YoY
This collaboration underscores WOTR's unwavering commitment to strengthening rural communities against the unpredictable variations of climate change
General Medicine grows 5% and Vaccines 10% led by Shingrix
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Total transaction value of the divestment is Rs. 3,660 million
Subscribe To Our Newsletter & Stay Updated
